|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003280,
umls-concept:C0005821,
umls-concept:C0009429,
umls-concept:C0010072,
umls-concept:C0012984,
umls-concept:C0016011,
umls-concept:C0019134,
umls-concept:C0026336,
umls-concept:C0031809,
umls-concept:C0231491,
umls-concept:C0286590,
umls-concept:C0556895,
umls-concept:C0597357,
umls-concept:C1280500
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1996-11-29
|
|
pubmed:abstractText |
There is a paucity of data regarding the antithrombotic pharmacology of the drug-drug interactions between the newer anticoagulant and antiplatelet agents. In this investigation, we have studied the antithrombotic effects of combinations of minimum effective doses of the glycoprotein IIb-IIIa receptor antagonist 7E3 [murine F(ab')2] with both heparin and the novel tripeptide arginal antithrombin efegatran (LY294468) in a canine model of coronary artery thrombosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0009-7322
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1719-25
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8840866-Animals,
pubmed-meshheading:8840866-Antibodies, Monoclonal,
pubmed-meshheading:8840866-Bleeding Time,
pubmed-meshheading:8840866-Blood Pressure,
pubmed-meshheading:8840866-Coronary Thrombosis,
pubmed-meshheading:8840866-Dogs,
pubmed-meshheading:8840866-Drug Therapy, Combination,
pubmed-meshheading:8840866-Female,
pubmed-meshheading:8840866-Fibrinolytic Agents,
pubmed-meshheading:8840866-Heart Rate,
pubmed-meshheading:8840866-Heparin,
pubmed-meshheading:8840866-Immunoglobulin Fab Fragments,
pubmed-meshheading:8840866-Male,
pubmed-meshheading:8840866-Oligopeptides,
pubmed-meshheading:8840866-Platelet Aggregation Inhibitors,
pubmed-meshheading:8840866-Platelet Glycoprotein GPIIb-IIIa Complex
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis.
|
|
pubmed:affiliation |
Cardiovascular Research Division, Lilly Research Laboratories, Eli Lilly and Co. Indianapolis, Ind., USA.
|
|
pubmed:publicationType |
Journal Article
|
